CURRENT
ISSUE
1713

The FDA has licensed Capvaxive (PCV21; Merck), a 21-valent pneumococcal conjugate vaccine, for prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia in adults. Four other pneumococcal vaccines are currently available in the US: Prevnar 20 (PCV20), Vaxneuvance (PCV15), and Prevnar 13 (PCV13) are conjugate vaccines licensed for use in persons ≥6 weeks old, and Pneumovax 23 (PPSV23) is a pneumococcal polysaccharide vaccine licensed for use in persons ≥2 years old (see Table 1).1

 Continue reading

Coming Soon
Drugs for Hepatitis C
Extended-Release Carbidopa/Levodopa (Crexont) for Parkinson's Disease
Eroxon OTC Topical Gel for Erectile Dysfunction
FluMist Influenza Vaccine for Self-Administration